학술논문
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region
Document Type
article
Author
Marc Emmenegger; Elena De Cecco; David Lamparter; Raphaël P.B. Jacquat; Julien Riou; Dominik Menges; Tala Ballouz; Daniel Ebner; Matthias M. Schneider; Itzel Condado Morales; Berre Doğançay; Jingjing Guo; Anne Wiedmer; Julie Domange; Marigona Imeri; Rita Moos; Chryssa Zografou; Leyla Batkitar; Lidia Madrigal; Dezirae Schneider; Chiara Trevisan; Andres Gonzalez-Guerra; Alessandra Carrella; Irina L. Dubach; Catherine K. Xu; Georg Meisl; Vasilis Kosmoliaptsis; Tomas Malinauskas; Nicola Burgess-Brown; Ray Owens; Stephanie Hatch; Juthathip Mongkolsapaya; Gavin R. Screaton; Katharina Schubert; John D. Huck; Feimei Liu; Florence Pojer; Kelvin Lau; David Hacker; Elsbeth Probst-Müller; Carlo Cervia; Jakob Nilsson; Onur Boyman; Lanja Saleh; Katharina Spanaus; Arnold von Eckardstein; Dominik J. Schaer; Nenad Ban; Ching-Ju Tsai; Jacopo Marino; Gebhard F.X. Schertler; Nadine Ebert; Volker Thiel; Jochen Gottschalk; Beat M. Frey; Regina R. Reimann; Simone Hornemann; Aaron M. Ring; Tuomas P.J. Knowles; Milo A. Puhan; Christian L. Althaus; Ioannis Xenarios; David I. Stuart; Adriano Aguzzi
Source
iScience, Vol 26, Iss 2, Pp 105928- (2023)
Subject
Language
English
ISSN
2589-0042
Abstract
Summary: Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital patients and blood donors (n = 72′250) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). We found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 to 12.2% in mid-December 2020. A follow-up health survey indicated that about 10% of patients infected with wildtype SARS-CoV-2 sustained some symptoms at least twelve months post COVID-19. Crucially, we found no evidence of a difference in long-term complications between those whose infection was symptomatic and those with asymptomatic acute infection. The cohort of asymptomatic SARS-CoV-2-infected subjects represents a resource for the study of chronic and possibly unexpected sequelae.